Neues zur Therapie von Non-Hodgkin-Lymphomen, Morbus Hodgkin und Multiplen Myelom

Bei der Jahrestagung der American Society of Oncology (ASCO) 2016 wurden neben Daten zu soliden Tumoren auch Studien zu hämatologischen Erkrankungen vorgestellt. Im Folgenden sollen die jeweiligen Kernbotschaften dieser Arbeiten zu Non-Hodgkin-Lymphomen, zum Morbus Hodgkin und zum Multiplen Myelom vermittelt werden.

At the annual meeting of the American Society for Oncology (ASCO) in 2016 new data were presented from studies on hematological diseases as well as solid tumors. The key messages from the respective reports of these studies on non-Hodgkin lymphomas, Hodgkin’s disease and multiple myeloma are reviewed in this contribution.

Key words

Annual Meeting of the American Society for Oncology - ASCO - hematological diseases - non-Hodgkin lymphoma - Hodgkin’s disease - multiple myeloma

• Literatur

• 1 Lorenz HTrumper, Gerald Wulf et al. Deutsche Studiengruppe Hochmaligne Lymphome DSHNHL; Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final results of 116 patients treated in the international ACT-2 phase III trial. J Clin Oncol 2016; 34 (suppl; abstr 7500)
• 2 Hochhaus A, Masszi T, Giles FJ et al. Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: Results from the ENESTFreedom study. J Clin Oncol 2016; 34 (suppl; abstr 7001)
• 3 Rubenstein JL, Fraser E, Formaker P. Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma. J Clin Oncol 2016; 34 (suppl; abstr 7502)
• 4 Rummel MJ, Knauf W, Goerner M. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol 2016; 34 (suppl; abstr 7503)
• 5 Zohren F, Bruns I, Pechtel S. Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy. Blood 2015; 126: 1407-1414
• 6 Pieternella J, Lugtenburg PJ, de Nully BrownP. Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study. J Clin Oncol 2016; 34 (suppl; abstr 7504)
• 7 Chen RW, Zinzani PL, Fanale MA. Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study. J Clin Oncol 2016; 34 (suppl; abstr 7555)
• 8 Younes A, Santoro A, Zinzani PL. Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) – A phase 2 study. J Clin Oncol 2016; (suppl; abstr 7535)
• 9 Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015; 372: 311-319
• 10 Attal M, Palumbo A, Holstein SA. Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS). J Clin Oncol 2016; 34 (suppl; abstr 8001)
• 11 Palumbo A, Chanan-Khan AAA, Weisel K. Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. J Clin Oncol 2016; 34 (suppl; abstr LBA4)